Learn what retatrutide is, how this next‑generation triple agonist (GLP‑1, GIP, and glucagon) works for weight loss, obesity, and metabolic health, and see key phase 2 clinical trial results on body‑weight reduction and cardiometabolic benefits.
Learn what retatrutide is, how its triple agonist action on GLP‑1, GIP, and glucagon receptors works, and why early clinical trials show up to 24% weight loss and major improvements in blood sugar control.
Discover why retatrutide is being called the “next‑gen tirzepatide.” Learn how this triple GIP, GLP‑1, and glucagon receptor agonist drives bariatric‑level weight loss, boosts energy expenditure, and improves cardiometabolic health in obesity.